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TransplantatABSTRACT
Introduction. The aim of this preliminary work is to analyze the clinical features of 52
patients with a functional transplanted kidney for >25 years (all ﬁrst transplant and all
deceased donor recipients) and to compare with a similar though more complete study from
Hôpital Necker-Paris 2012.
Methods. The mean graft survival at 25 years is 12.7% and at 30 years is 10%. The actual
mean serum creatinine concentration is 1.3 mg/L. We analyzed recipient age (mean, 35.9
years) and gender (29 men and 23 women). Donor age was 26.7  10.3 years. Seven pa-
tients (13.4%) were transplanted with 1 HLA mismatch, 42.3% with 2 mismatches, and
44.2% with 3 mismatches. Mean cold ischemia time was 15.45  7.7 hours. Of the re-
cipients, 76% had immediate graft function; 38% experienced 1 acute rejection episode
and 4 patients had 2 rejection crises. The initial immunosuppressive regimen was azathi-
oprine (AZA) þ prednisolone (Pred) in 14 patients, cyclosporin (CSA) þ Pred in 13 pa-
tients, and CSA þ AZA þ Pred in 25 patients. Of these patients, 19% maintained their
initial regimen, and 54% (28 patients) were very stable on a mixed CSA regimen for >25
years.
Results. We present the major complications (diabetes, neoplasia, and hepatitis C virus
positivity).
Conclusion. Our results in deceased donor kidney recipients for >25 years are similar to
the mixed population (deceased donors and living donors) presented by the Necker group,
although 54% of our patients remain on CSA immunosuppression, contradicting the idea
that its use is not compatible with good long-term kidney function in transplant recipients.*Address correspondence to Fernanda Rego, Unidade de
Transplantação Renal, Hospital da Cruz Vermelha Portuguesa,
Rua Duarte Galvão, n 54 1549-008 Lisboa, Portugal. E-mail:
fewrnandarego@gmail.comCONSIDERABLE progress has been made in the careof transplant recipients regarding organ preservation,
quality, and quantity for life of these patients. Mainly, im-
provements in the management of complications allowed
the emergence of a group of long-term survivors who were
transplanted several decades ago. These patients constitute
a unique population about whom few data have been pub-
lished. The few publications [1e3] of patients with func-
tioning renal allograft for >25 years are usually related to a
mixed population of living-related donors (usually the larger
percentage) and deceased donor transplant recipients.
Our unit performed our ﬁrst renal transplantation in June
1980. We celebrated our 500th in 1990 and our 1000th
procedure in 1997. We selected a group of patients with
functioning kidney graft transplanted 20 years ago, alllsevier Inc. All rights reserved.
enue South, New York, NY 10010-1710
ion Proceedings, 47, 967e970 (2015)from a deceased donor. The aim of the work was to present
and compare the clinical characteristics of this unique
population.
PATIENTS AND METHODS
From July 1980 to January 15, 1994 (20 years ago), we performed
759 transplants; of those recipients, 110 maintain a functioning
kidney on follow-up, 52 for >25 years and 11 for >30 years. The



















Fig 1. Patient ﬂow of 408 transplant recipients.
968 REGO, ALÇÂNTARA, BUINHO ET AL52 patients included in the study, were all transplanted and main-
tained in follow-up in our unit.
Patient data from July 1980 to January 15, 2014, were collected
individually patient’s medical records and transferred to a database.
All patients have a functional ﬁrst kidney transplant. From 1980 to
15 July 1989, we performed 408 kidney transplants: all ABO-
compatible and with negative cross-matching on complement-
dependent cytotoxicity assays. Of the 408 patients transplanted 25
years ago, 17 were lost to follow-up, 198 returned to dialysis, 141
died, and 52 (12.75%) are well and stable (Fig 1). Of the 110 pa-
tients transplanted through January 1984, 11 (10%) maintained a
graft functioning for 30 years. Time from transplant is a minimum
of 25 years and a maximum of 33.3 years.RESULTS
The donors of the 52 patients were mainly young adults
(mean age, 26.7  10.3 years). Recipients had a mean age of
35.9  8.04 years and their end-stage renal disease wasFig 2. Initial and current
immunosuppression.owing to chronic glomerulonephritis (n ¼ 22), hereditary
renal disease (n ¼ 4), primary urologic disease (n ¼ 5),
unknown ethology (n ¼ 11), primary immunologic disease
(n ¼ 6), and chronic pyelonephritis (n ¼ 4).
Initial immunosuppression was with antimetabolites and
prednisone in 14 patients, cyclosporine and prednisone in 13
patients, and a triple regimen in 25 (Fig 2).Of the patients, 76%
had immediate renal function and 24% experienced acute
tubular necrosis. In 38%of the patients, there was an episode of
acute rejection and 4 patients had 2 episodes. Mean serum
creatinine at 1 year posttransplant was 106.08 30.94 mmol/L.
The current creatinine level is 114.923 61.88 mmol/L (Fig 3).
Table 1 presents the main patient and donor characteristics.
During the follow-up of 25 years, 8 patients (15%)
developed diabetes mellitus. Only 1 patient with diabetes is
insulin dependent; there are no major complications and
the hemoglobin A1c level is good.
Two patients experienced premature aseptic necrosis of
the head of the femur (at 2 and 4 years posttransplant)
probably related to high-dose steroids. The older one was 53
years old and treated with methylprednisolone 500 mg/d for
7 days to treat 2 rejection crises.
Five patients had solid organ cancer: 2 breast, 1 bladder, 1
prostate, and 1 uterus cervix. All these underwent chemo-
therapy and/or radiotherapy and/or surgery. They lowered the
immunosuppression regimen andwere switched tomammalian
target of rapamycin antagonists (Fig 2). One patient had
esophagus lymphoma 8 years posttransplantation. He stopped
all the immunosuppression, underwent chemotherapy for 4
months, and his condition improved. He has been without any
immunosuppression for 11 years maintaining a normal func-
tioning graft. After all these years, his kidney function began
to deteriorate. Four years ago, everolimus 50 mg bid was
Fig 3. Mean blood creatinine at the ﬁrst year (red points: 1.28 0.35 mg/dL [range, 0.7e2.4]) versus the current year (January 15, 2014;
blue points: 1.39  0.6 mg/dL [range, 0.7e4.0]).
Table 1. Patient and Allograft Characteristics (n [ 52)
Characteristic Value
Donor age (y) 26.7  10.3
Recipient age (y) 35.9  8.04
Recipient sex ratio (F/M) 0.79
Nephrectomy, n (%) 2 (3.8)
HLA mismatches (mean) 2.307
Cold ischemia time (h) 15.45  7.7
Immunosuppressive regimen (day 1), n (%)
Antilymphocytes globulins 2 (3.8)
Azathioprine þ prednisone 14 (26.9)
Cyclosporine þ prednisone 13 (25)
Cyclosporine þ azathioprine þ prednisone 25 (48)
Current immunosuppressive regimen, n (%)
Azathioprine þ prednisone 8 (15.3)
Cyclosporine þ prednisone 14 (26.9)
Cyclosporine þ azathioprine þ prednisone 4 (7.7)
Cyclosporine þ azathioprine 7 (21.1)
Cyclosporine þ MMF 3 (5.8)
Only new immunossupressors 16 (31)
Total patients in cyclosporin associations 28 (54)
Graft kidney immediate functioning 40 (76)
One acute rejection episode 20 (38)
Two acute rejection crises 4 (7.7)
Mean blood creatinine at 1 year 1.2  0.35 mg/dL;
106.08  30.94
mmol/L
Current mean blood creatinine 1.3 mg/dL
LONG-TERM SURVIVAL 969prescribed, and his kidney function returned to normal levels.
Three patients had severe skin cancer (all in the azathioprine
group), which improved dramatically after changing to myco-
phenolate mofetil or mammalian target of rapamycin in-
hibitors. All required surgery and improved afterward. Three
patients were positive for hepatitis C virus at the time of
transplantation, but none of them have experienced a major
complication to date.
DISCUSSION
Our report is retrospective, only concerns clinical data, and
these are the features we compare with the similar reports in
the literature [1e3]. The Hôpital-Necker study [2] analyzed
both clinical and immunologic features of very long-term
survivors of renal transplant. In our study, only clinical
data is available. Even though 44% of the patients in the
Necker study received living donor grafts, a group known
for better outcomes, our results on long-term graft survival
are similar (10% vs 11.2%) at 30 years. Donor age is similar.
Cold ischemia time for cadaveric donors is also similar. The
etiology of recipient end-stage renal disease is not different,
with a predominance of nonprimary immunologic disorders.
However, recipient age is higher in our group (35.9 vs 27.1
years in the Necker group) and initial immunosuppression is
also different; the Necker data group reviewed data through
1978, whereas we include patients transplanted and treated
through 1989. The immunosuppressive regimen at 30 years
includes quite a few patients (3% in Necker group) on
calcineurin inhibitors; 54% of our patients are maintained
on a mixed CSA regimen (Figs 2 and 3).
The Necker group attributes the good functional results
of their patients to the absence of calcineurin inhibitor
use, which they believe translated into a prevention of
chronic nephrotoxicity. Our results contradict their ﬁnd-
ings; 54% of our patients are still on a calcineurininhibitorebased mixed regimen, in accordance with other
studies demonstrating that immune injury is the leading
cause of graft damage and loss and that calcineurin in-
hibitor nephrotoxicity has a minor impact on chronic
allograft nephropathy [4e7].
In conclusion, deceased donor transplant recipients can
survive with good functional kidneys for a long timed>25
970 REGO, ALÇÂNTARA, BUINHO ET ALand >30 yearsdwith success similar to those receiving have
a living donor allograft. One of the most important clinical
determinants seems to be in every study a low cold ischemia
time from donors, as well as younger age donors. We think
that maintaining follow up in the same center all over the
years is also a good determinant for good results (we only
lost for follow up 17/408 patients and in Necker also 40/499.
We can also conclude that CSA nephrotoxicity has low if
any impact on long-term graft survival and can result in
good graft function if used in adequate doses.REFERENCES
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